Recall of Philips Respironics Trilogy Evo O2 Ventilator for Safety Issue
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Philips Respironics is recalling 113,717 units of its Trilogy Evo O2 ventilator due to potential discrepancies in tidal volume when using non-pneumatic nebulizers.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 8, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, fda, Devices) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
Recall Article: Philips Respironics Trilogy Evo O2
What Happened
Philips Respironics, Inc. is initiating a voluntary recall of its Trilogy Evo O2 ventilator devices because using non-pneumatic nebulizers may result in a discrepancy between the set tidal volume and the tidal volume received by the patient.
Which Products Are Affected
The affected products are the Philips Respironics Trilogy Evo O2 with Software Version 1.05.15.00. This includes all model numbers, all UDIs, and all serial numbers. A total of 113,717 units are affected, with distribution nationwide in the United States and to various international countries.
What You Should Do
Consumers who have received a letter from the firm should follow the instructions provided as part of this voluntary recall.
Why This Matters
This recall is significant because the discrepancy could impact patient safety for those using the ventilator for breathing support, potentially leading to health risks.
Source
This information is from the FDA, recall number Z-1615-2026.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.